drugset
drugset / Trial / NCT02755155

Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients

NCT02755155 ↗

Phase 4 Terminated 138 enrolled University Hospital, Strasbourg, France
RandomizedParallel-groupOpen-labelTreatment

Summary

Primary purpose : mortality at Day 28 Secondary purposes : * Daily SOFA (Sequential Organ Failure Assessment) score lessening within Intensive Care Unit (ICU) * Duration of increasing doses of norepinephrine infusion to maintain target mean arterial pressure * Number of care-related infections within ICU

Timeline

Start
2016-09
Primary completion
2019-08-10
Completion
2019-08-10

Outcome

Outcome not reported

Stopped (Enrollment): “too many patients were expected and the investigative team would not be able to recruit this number”

Drugs

EvaluationDrugModalityDoseRoute
Subject Human Serum Albumin Protein / enzyme biologic 4 % —
Subject Human Serum Albumin Protein / enzyme biologic 20 % —

Indications

No indication recorded.